A Comprehensive Analysis of FGF / FGFR Signaling Alteration in NSCLC : Implications in Prognosis and Microenvironment
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Ziling Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Tumor Microenvironment, Lung Neoplasms, Fibroblast Growth Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, National Key Research and Development Program of China Stem Cell and Translational Research, Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology Committee.
Abstract (Originalsprache)
Fibroblast Growth Factor (FGF) ligands and their receptor have been identified as the potent target in non–small cell lung cancer (NSCLC). However, the clinicopathological and microenvironmental characteristics of FGF/FGFR in NSCLC remain poorly elucidated. Here, we summarize 4656 NSCLCs and analyze clinicopathological features in 478 FGF/FGFR altered cases. AI analysis and multiplex immunofluorescence staining are used to reveal microenvironment features. First, around 10.27% NSCLC carry FGF/FGFR variant. Squamous cell carcinoma (41.95%) is much more than adenocarcinoma (8.32%). In 118 pathogenic variant (PV) cases, the most frequent variant is FGF/FGFR copy number increase (83.05%), the second is FGFR gene fusion (11.86%). Surprisingly, CCND1 always co‐amplifies with FGF19 (100.00%). Furthermore, FGF PV is an independent risk factor for poor outcomes (overall survival: HR = 3.781, disease‐free survival: HR = 3.340). And one‐third of FGFR3‐TACC3 fusion cases show clear cytoplasm in histology. Either CCND1/FGF19 co‐amplification or KRAS co‐mutation is closely related to cigarette exposure, and KRAS co‐mutation acts as an independent factor of poor prognosis. Finally, the FGF/FGFR1/NOTCH1 within RB1 variant group has a remarkably high ratio of inner‐tumor CD8+ T cell infiltration, non‐exhausted T cells, exhausted T CD8+PD‐1+LAG3− cells, and T RM CD8+CD69+CD103+ cells. Overall, this study provides a comprehensive analysis of FGF/FGFR alteration in NSCLC. The FGF/FGFR alteration mainly arises in squamous cell carcinoma. Both FGF PV and KRAS are the independent factors for poor prognosis. To our knowledge, this is the first report to describe an inflamed microenvironment recruited by NOTCH1 / RB1 co‐mutation, indicating potential benefit from immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
- School of Computer Science, Fudan University, Shanghai, China.
- Butiange Co. Ltd, Shanghai, China.
- Alpha X Biotech (Beijing) Co., Beijing, China.
ORCID-Profile: Ziling Huang
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- National Key Research and Development Program of China Stem Cell and Translational Research
- Institution and Governmental Cooperative Project, Shanghai Xuhui District Science and Technology Committee
Zitieren
APA
Huang, Z., Li, L., Cai, X., Wang, S., Jia, Y., & Li, Y. (2025). A Comprehensive Analysis of FGF / FGFR Signaling Alteration in NSCLC : Implications in Prognosis and Microenvironment. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70016
Vancouver
Huang Z, Li L, Cai X, Wang S, Jia Y, Li Y. A Comprehensive Analysis of FGF / FGFR Signaling Alteration in NSCLC : Implications in Prognosis and Microenvironment. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70016
BibTeX
@article{Huang2025,
author = {Huang, Ziling and Li, Leyao and Cai, Xu and Wang, Shen and Jia, Yun and Li, Yuan},
title = {A Comprehensive Analysis of FGF / FGFR Signaling Alteration in NSCLC : Implications in Prognosis and Microenvironment},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70016}
}
EUVIMED